Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
OXY111A
DRUG
2 trials
Sponsors
Wojskowy Instytut Medyczny Panstwowy Instytut Badawczy
, University of Zurich
Conditions
COVID-19 and other pulmonary parenchyma infections.
Cholangiocarcinoma
Colorectal Neoplasms
Hepatocellular Cancer
Pancreatic Neoplasms
Phase 1
Effects of OXY111A in Primary and Secondary Hepato-Pancreato-Biliary Neoplasm
NCT02528526
University of Zurich
Cholangiocarcinoma, Colorectal Neoplasms, Hepatocellular Cancer +1
Start: 2014-02-28
End: 2016-12-31
Target: 69
Updated: 2015-08-19
Phase 2
ITPP as an adjunctive treatment for progressive respiratory failure in COVID-19 and other pulmonary parenchymal infections - a randomized, double-blind, non-commercial phase II clinical trial [BREATH2]
Completed
CTIS2024-517878-21-00
Wojskowy Instytut Medyczny Panstwowy Instytut Badawczy
COVID-19 and other pulmonary parenchyma infections.
Start: 2023-11-28
End: 2025-06-11
Target: 100
Updated: 2025-02-10
Related Papers
Phase Ib dose-escalation study of the hypoxia-modifier myo-inositol trispyrophosphate in patients with hepatopancreatobiliary tumors
British journal of surgery
2022-05-31
1 citations
Phase Ib dose-escalation study of the hypoxia-modifier Myo-inositol trispyrophosphate in patients with hepatopancreatobiliary tumors.
2021-06-21
15 citations
First evidence of antitumor activity of ITPP, a novel hypoxia-modifier: Results of a phase Ib trial
Annals of Oncology
2018-12-01
Development of OXY111A, a novel hypoxia-modifier as a potential antitumor agent in patients with hepato-pancreato-biliary neoplasms - Protocol of a first Ib/IIa clinical trial.
2016-10-19
18 citations